Related Experiment Video

Updated: Aug 26, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.8K

The NLRP3 inflammasome as a new target in respiratory disorders treatment

Katarzyna Leszczyńska1, Dominika Jakubczyk1, Sabina Górska1

  • 1Laboratory of Microbiome Immunobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

Frontiers in Immunology
|October 7, 2022
PubMed

Insights

New research highlights the NLRP3 inflammasome's role in airway inflammatory diseases like asthma and COPD. Probiotics show promise in potentially inhibiting this pathway, offering new therapeutic avenues for respiratory conditions.

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Molecular Biology

Background:

  • Rising incidence of respiratory disorders including rhinitis, asthma, and COPD.
  • Current treatments (antihistamines, glucocorticosteroids) offer symptomatic relief with side effects.
  • Limited efficacy of allergen immunotherapy for specific allergies.

Purpose of the Study:

  • To review the role of NLRP3 inflammasome in the pathogenesis of allergic rhinitis, asthma, and COPD.
  • To explore the potential of probiotics as modulators of NLRP3 inflammasome activity.
  • To identify novel therapeutic targets for airway inflammatory diseases.

Main Methods:

  • Literature review focusing on NLRP3 inflammasome activation in airway inflammation.
  • Analysis of studies investigating the link between respiratory diseases and inflammasome pathways.
  • Examination of research on probiotic effects on NLRP3 inflammasome.

Main Results:

  • NLRP3 inflammasome activation is implicated in the development of allergic rhinitis, asthma, and COPD.
  • This inflammasome represents a potential therapeutic target for these conditions.
  • Probiotics demonstrate modulatory properties that may inhibit NLRP3 inflammasome.

Conclusions:

  • NLRP3 inflammasome is a key contributor to airway inflammation in common respiratory diseases.
  • Targeting the NLRP3 inflammasome could offer novel treatment strategies.
  • Probiotics present a promising avenue for modulating NLRP3 inflammasome and managing respiratory disorders.
Keywords:
IL-1βNLRP3 inflammasomeallergic asthmaallergic rhinitisanti-inflammatorychronic obstructive pulmonary diseaseprobioticstreatment

More Related Videos

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.0K
The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice12:27

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice

Published on: April 2, 2014

16.8K

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
555
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
822
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
417
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
185
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
529